Literature DB >> 23149559

Higher coated-platelet levels are associated with stroke recurrence following nonlacunar brain infarction.

Calin I Prodan1, Julie A Stoner, Linda D Cowan, George L Dale.   

Abstract

Coated-platelets are procoagulant platelets observed upon dual-agonist stimulation with collagen and thrombin. Coated-platelet levels are elevated in patients with nonlacunar (large-vessel) ischemic stroke and decreased in patients with spontaneous intracerebral hemorrhage as compared with controls. The purpose of this study was to investigate a possible relationship between coated-platelet levels and stroke recurrence in patients with nonlacunar ischemic stroke. We assayed coated-platelet levels in 190 consecutive patients with nonlacunar stroke who were followed for up to 12 months; 20 subjects experienced recurrent stroke. Subjects were categorized into tertiles of coated-platelet levels. The distributions of time-to-recurrent stroke were estimated for each tertile using cumulative incidence curves and compared statistically using a log-rank test. The cumulative incidence of recurrent stroke at 12 months differed among the coated-platelet tertiles: 2% for the first tertile (lowest coated-platelet levels), 18% for the second tertile, and 17% for the third tertile (overall log-rank test, P=0.019). These data suggest that higher levels of coated-platelets, measured shortly after a nonlacunar stroke, are associated with an increased incidence of stroke recurrence. This observation offers an additional tool for identifying patients at highest risk for stroke recurrence following a nonlacunar (large-vessel) infarct.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23149559      PMCID: PMC3564199          DOI: 10.1038/jcbfm.2012.168

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  30 in total

1.  Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin.

Authors:  L Alberio; O Safa; K J Clemetson; C T Esmon; G L Dale
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

2.  Role of mitochondrial permeability transition pore in coated-platelet formation.

Authors:  Gyula Remenyi; Robert Szasz; Paul Friese; George L Dale
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-12-09       Impact factor: 8.311

3.  Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface.

Authors:  George L Dale; Paul Friese; Peter Batar; Stephen F Hamilton; Guy L Reed; Kenneth W Jackson; Kenneth J Clemetson; Lorenzo Alberio
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

Review 4.  Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke.

Authors:  Peter M Rothwell; Ale Algra; Pierre Amarenco
Journal:  Lancet       Date:  2011-05-14       Impact factor: 79.321

5.  Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates.

Authors:  P Peduzzi; J Concato; A R Feinstein; T R Holford
Journal:  J Clin Epidemiol       Date:  1995-12       Impact factor: 6.437

6.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.

Authors:  Hans-Christoph Diener; Julien Bogousslavsky; Lawrence M Brass; Claudio Cimminiello; Laszlo Csiba; Markku Kaste; Didier Leys; Jordi Matias-Guiu; Hans-Jürgen Rupprecht
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

7.  Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.

Authors:  Eric J Topol; Donald Easton; Robert A Harrington; Pierre Amarenco; Robert M Califf; Carmen Graffagnino; Stephen Davis; Hans-Christophe Diener; James Ferguson; Desmond Fitzgerald; Jeffrey Granett; Ashfaq Shuaib; Peter J Koudstaal; Pierre Theroux; Frans Van de Werf; Kristina Sigmon; Karen Pieper; Marc Vallee; James T Willerson
Journal:  Circulation       Date:  2003-07-21       Impact factor: 29.690

8.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

Review 9.  Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies.

Authors:  J K Lovett; A J Coull; P M Rothwell
Journal:  Neurology       Date:  2004-02-24       Impact factor: 9.910

10.  Underestimation of the early risk of recurrent stroke: evidence of the need for a standard definition.

Authors:  Andrew J Coull; Peter M Rothwell
Journal:  Stroke       Date:  2004-06-10       Impact factor: 7.914

View more
  10 in total

1.  Coated platelets function in platelet-dependent fibrin formation via integrin αIIbβ3 and transglutaminase factor XIII.

Authors:  Nadine J A Mattheij; Frauke Swieringa; Tom G Mastenbroek; Michelle A Berny-Lang; Frauke May; Constance C F M J Baaten; Paola E J van der Meijden; Yvonne M C Henskens; Erik A M Beckers; Dennis P L Suylen; Marc W Nolte; Tilman M Hackeng; Owen J T McCarty; Johan W M Heemskerk; Judith M E M Cosemans
Journal:  Haematologica       Date:  2015-12-31       Impact factor: 9.941

2.  Necrotic platelets provide a procoagulant surface during thrombosis.

Authors:  Vu Minh Hua; Latasha Abeynaike; Elias Glaros; Heather Campbell; Leonardo Pasalic; Philip J Hogg; Vivien M Y Chen
Journal:  Blood       Date:  2015-10-16       Impact factor: 22.113

3.  Platelet necrosis mediates ischemic stroke outcome in mice.

Authors:  Frederik Denorme; Bhanu Kanth Manne; Irina Portier; Alicia S Eustes; Yasuhiro Kosaka; Benjamin T Kile; Matthew T Rondina; Robert A Campbell
Journal:  Blood       Date:  2020-02-06       Impact factor: 25.476

Review 4.  Platelet Subtypes in Inflammatory Settings.

Authors:  Muataz Ali Hamad; Krystin Krauel; Nancy Schanze; Nadine Gauchel; Peter Stachon; Thomas Nuehrenberg; Mark Zurek; Daniel Duerschmied
Journal:  Front Cardiovasc Med       Date:  2022-04-07

Review 5.  Advances in Platelet Subpopulation Research.

Authors:  Gabriela Lesyk; Paul Jurasz
Journal:  Front Cardiovasc Med       Date:  2019-09-13

6.  Antibody-mediated procoagulant platelet formation in COVID-19 is AKT dependent.

Authors:  Lisann Pelzl; Anurag Singh; Jonas Funk; Andreas Witzemann; Irene Marini; Jan Zlamal; Karoline Weich; Wissam Abou-Khalel; Stefanie Hammer; Guenalp Uzun; Karina Althaus; Tamam Bakchoul
Journal:  J Thromb Haemost       Date:  2021-12-03       Impact factor: 16.036

7.  Effects of Platelet Agonists and Priming on the Formation of Platelet Populations.

Authors:  Alicia Veninga; Constance C F M J Baaten; Ilaria De Simone; Bibian M E Tullemans; Marijke J E Kuijpers; Johan W M Heemskerk; Paola E J van der Meijden
Journal:  Thromb Haemost       Date:  2021-10-24       Impact factor: 6.681

Review 8.  Brothers in arms: platelets and neutrophils in ischemic stroke.

Authors:  Frederik Denorme; John L Rustad; Robert A Campbell
Journal:  Curr Opin Hematol       Date:  2021-09-01       Impact factor: 3.218

9.  Platelet dysfunction in injured patients.

Authors:  Noelle N Saillant; Carrie A Sims
Journal:  Mol Cell Ther       Date:  2014-12-19

Review 10.  Procoagulant Phosphatidylserine-Exposing Platelets in vitro and in vivo.

Authors:  Emily C Reddy; Margaret L Rand
Journal:  Front Cardiovasc Med       Date:  2020-03-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.